<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02371681</url>
  </required_header>
  <id_info>
    <org_study_id>999915070</org_study_id>
    <secondary_id>15-I-N070</secondary_id>
    <nct_id>NCT02371681</nct_id>
  </id_info>
  <brief_title>NexGen EBA Radiologic and Immunologic Biomarkers of Sterilizing Drug Activity in Tuberculosis</brief_title>
  <official_title>NexGen EBA Radiologic and Immunologic Biomarkers to Enhance Early Bactericidal Activity Measurements of Sterilizing Drug Activity in Tuberculosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

      - Tuberculosis (TB) is a lung infection caused by bacteria. When people with TB cough, they
      may spread these bacteria. Researchers are looking for new TB medicines. They want to find a
      faster way to tell if a drug might combat TB.

      Objective:

      - To learn the effect of different anti-TB drugs on microbiological, radiographic and
      immunologic markers in people with TB.

      Eligibility:

      - Adults age 18-65 who weigh 30-90 kg and have common TB bacteria that can be treated with
      common TB medicines.

      Design:

        -  Participants will be admitted to the hospital for screening. They will have medical
           history, physical exam, and chest radiograph. They will give blood, urine, and sputum
           samples.

        -  Participants will be put in 1 of 8 groups.

        -  Participants will get one or a combination of TB medicines daily for about 14 days.

        -  Each day, participants:

        -  Will discuss side effects.

        -  May have a physical exam.

        -  Will spit mucus into a cup. They may breathe in saline water through a nebulizer to make
           them cough.

        -  Participants will have blood taken 3-4 times during the study

        -  Participants will have 2-3 Fluorodeoxyglucose Positron Emission Tomography/Computed
           Tomography (FDG-PET/CT) scans. FDG is a radioactive sugar molecule which helps measure
           TB disease in the lungs. It will be injected into a vein. Participants will lie in a
           scanner that takes pictures.

        -  Around study day 14, participants will leave the hospital. They will be referred to a
           local TB clinic. There they will get the standard 4 TB medicines. Those in group 8 will
           already be on these medicines and will have another FDG-PET/CT on day 28.

        -  Participants will be in the study for up to 28 days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Early bactericidal activity (EBA), which measures decline in serial sputum colony forming
      unit (CFU) counts over the first 2-14 days of treatment, has been used extensively as a means
      of initially evaluating the potency of individual or combinations of antituberculous agents.
      This approach is endorsed by the Global Alliance for TB Drug Development and the US FDA.
      However, EBA seems to correlate poorly with the relative ability of an agent to prevent
      relapse and produce a durable cure (often referred to as sterilizing activity ). The reasons
      for this discrepancy may have to do with a limitation of sputum measurements to capture
      populations that persist beyond airway surfaces in discrete lesions such as granulomas,
      nodules, or cavities. The elimination of these persistent populations depends on the
      pharmacodynamic properties of a regimen and may be better captured by biologic and functional
      markers that can reflect dynamic treatment effects within these relevant host environments.

      Recent studies of the response to TB chemotherapy have identified promising new biomarkers of
      sterilization in 2 areas. First, immunologic changes appear to have potential in small
      subject cohorts to predict sterilizing cure within 1 month after commencing treatment.
      Second, F-FDG PET/CT has been used in tuberculosis as a qualitative means of assessing drug
      response in small case series at multiple time points, starting as early as 1 month. PET
      activity reflects uptake and phosphorylation of FDG by neutrophils and macrophages, and CT
      provides structural information on disease pathology. Hence, PET/CT data may offer additional
      insights into lesion-specific sterilizing activity. This study will add 18F-FDG PET/CT scans
      and immunological assays at 0, 2, and (in the HRZE arm) 4 weeks to standard EBA methodology
      using regimens containing isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), moxifloxacin
      (MXF), and ethambutol (EM). We hypothesize that drug regimens associated with higher
      sterilizing activity (e.g., containing rifampin or pyrazinamide) will show distinctive early
      cytokine and chemokine patterns and discrete, quantifiable changes on PET/CT in certain
      lesion types during the 2-week period, compared to drug regimens with poor sterilizing
      activity (e.g., containing isoniazid or moxifloxacin). Demonstration of such an association
      would provide rationale for including radiologic and immunologic analysis, alongside
      conventional EBA, in early phase clinical studies of novel drugs, and would also provide
      important new insights into the biology of human and bacterial responses to TB drugs.

      PRIMARY OBJECTIVE:

      To characterize, in the context of a standard EBA study, the effect of various
      antituberculosis drugs on radiographic and immunologic markers as measured by PET/CT and
      immunologic assays, in treatment-na(SqrRoot) ve subjects with pulmonary drug sensitive
      tuberculosis.

      SECONDARY OBJECTIVES:

        1. To describe the nature and magnitude of drug/regimen-specific PET/CT changes over the
           initial 14 days of therapy in pulmonary drug sensitive tuberculosis subjects.

        2. To describe the change in PET/CT signals after 2 and 4 weeks of standard therapy with
           HRZE.

        3. To describe the correspondence between change in PET/CT and standard EBA measures among
           following chemotherapeutic regimens: isoniazid (INH [H]), rifampin (RIF [R]),
           pyrazinamide (PZA [Z]), HZ, RZ, M (MXF [M]), MRZE, and HRZE.

        4. To compare the qualitative changes in PET/CT among H, R, Z, HZ, RZ, M, and MRZE with
           that of HRZE.

        5. To characterize EBA using time to liquid culture positivity (TTP).

        6. To compare absolute and dynamic profiles of immunological assays composed of specific
           chemokines and cytokines, at 0, 2, and (in HRZE arm) 4 weeks for each treatment regimen.

        7. Comparison of specific changes in PET/CT characteristics between combination regimens
           and their components

        8. Comparison of specific changes in immunologic markers between combination regimens and
           their components

        9. To compare drug and drug metabolite levels to changes in PET/CT signals

      Design:

      This is a prospective, randomized study of drug-na(SqrRoot) ve subjects in South Africa with
      smear-positive, drug-sensitive pulmonary tuberculosis.

      Population:

      N=160 drug-na(SqrRoot) ve, smear positive subjects with tuberculosis from Cape Town, Republic
      of South Africa

      Subject Participation Duration:

      2-6 weeks

      Estimated Time to Complete Enrollment:

      12 months
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 25, 2015</start_date>
  <completion_date type="Actual">November 14, 2017</completion_date>
  <primary_completion_date type="Actual">September 1, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To characterize, in the context of a standard EBA study, the effect of various antituberculosis drugs on radiographic and immunologic markers as measured by PET /CT and immunologic assays</measure>
    <time_frame>14 days</time_frame>
    <description>To characterize, in the context of a standard EBA study, the effect of various antituberculosis drugs on radiographic and immunologic markers as measured by PET /CT and immunologic assays, in subjects with drug sensitive pulmonary tuberculosis who have not received anti-TB treatment within the last 3 years.A description of the individual markers that change over time is of interest to better understand both the markers and the effects of each treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PET/CT Changes</measure>
    <time_frame>14 days</time_frame>
    <description>Correlation of PET/CT changes with treatment response, microbiologic and immunologic outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rank order of drugs</measure>
    <time_frame>14 days</time_frame>
    <description>Comparison of the rank order of drugs based upon bacteriologic, radiologic and immunologic features.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">262</enrollment>
  <condition>Pulmonary Tuberculosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TB drugs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment</intervention_name>
    <description>Different Drug combinations</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>PET/CT Scan</intervention_name>
    <description>PET/CT Scans</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sample Collection</intervention_name>
    <description>Sample Collection</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

               1. Age 18 to 65 years with body weight from 30 kg to 90 kg

               2. Sputum acid-fast bacilli (AFB) smear positive (at least 1+ on the WHO
                  International Union Against Tuberculosis and Lung Disease scale)

               3. Likely able to produce approximately 10 mL of sputum per day

               4. Xpert MTB/RIF-confirmed M.tb

               5. Rifampin-sensitive pulmonary tuberculosis as indicated by Xpert MTB/RIF

               6. ALT &lt;3X upper limit of normal, creatinine &lt;2X upper limit of normal

               7. Willingness to have samples stored

        EXCLUSION CRITERIA:

          1. Clinically suspected disseminated TB or acuity of illness too much as deemed by
             clinicians

          2. Has been treated for tuberculosis within the past 3 years

          3. Treatment with agents known to have anti-tuberculosis activity (e.g.,
             fluoroquinolones, linezolid) for any indications during the current episode of
             clinical illness or within 2 months prior to screening, whichever is longer

          4. Cirrhosis or chronic kidney disease

          5. Disease complications or concomitant illness that might compromise safety or the
             interpretation of trial endpoints, such as known diagnosis of chronic inflammatory
             condition (e.g., sarcoidosis, rheumatoid arthritis, and connective tissue disorder)

          6. Use of immunosuppressive medications, such as TNF-alpha inhibitors or systemic or
             inhaled corticosteroids, within 2 weeks prior to screening

          7. Subjects with diabetes, point of care HbA1c above 6.5, or random glucose over 200
             mg/dL

          8. Conditions which compromise the subject s ability to take or absorb oral drugs

          9. Normal PA-Chest radiograph, determined during screening

         10. Total lung (left or right) collapse on PA-Chest radiograph

         11. HIV positive

         12. Pregnant or breastfeeding

         13. Any other condition that, in the responsible clinician s judgment, renders a subject
             too sick to safely tolerate 2 weeks study therapy

         14. Any condition that constitutes a contraindication to any of the drugs to be used on
             any study arms
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clifton E Barry, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stellenbosch University, Faculty of Medicine and Health Sciences</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TASK Applied Sciences</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <reference>
    <citation>Dartois V, Barry CE. Clinical pharmacology and lesion penetrating properties of second- and third-line antituberculous agents used in the management of multidrug-resistant (MDR) and extensively-drug resistant (XDR) tuberculosis. Curr Clin Pharmacol. 2010 May;5(2):96-114. Review.</citation>
    <PMID>20156156</PMID>
  </reference>
  <reference>
    <citation>Goo JM, Im JG, Do KH, Yeo JS, Seo JB, Kim HY, Chung JK. Pulmonary tuberculoma evaluated by means of FDG PET: findings in 10 cases. Radiology. 2000 Jul;216(1):117-21.</citation>
    <PMID>10887236</PMID>
  </reference>
  <reference>
    <citation>Jindani A, Dor√© CJ, Mitchison DA. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med. 2003 May 15;167(10):1348-54. Epub 2003 Jan 6.</citation>
    <PMID>12519740</PMID>
  </reference>
  <verification_date>July 20, 2020</verification_date>
  <study_first_submitted>February 25, 2015</study_first_submitted>
  <study_first_submitted_qc>February 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2015</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment-Response</keyword>
  <keyword>Radiological Imaging</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Antitubercular Agents</keyword>
  <keyword>Log-CFU Reduction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

